Table 1.
Baseline Demographic and Clinical Characteristics*
| Characteristic | Darunavir/Ritonavir 800/100 mg Once-Daily Group 1 |
Darunavir/Ritonavir 800/100 mg Plus (Group 2) |
|
|---|---|---|---|
| Etravirine 200 mg Twice-Daily Group 2A |
Etravirine 400 mg Once-Daily Group 2B |
||
| N | 16 | 6 | 9 |
| Gender | |||
| Male | 8 (50) | 3 (50) | 3 (33.3) |
| Race/Ethnicity | |||
| African American, non-Hispanic | 11 (68.8) | 2 (33.3) | 8 (89.9) |
| White, non-Hispanic | 0 | 2 (33.3) | 1 (11.1) |
| Hispanic | 5 (31.2) | 2 (33.4) | 0 |
| Tanner Stage | |||
| 1 | 0 | 0 | 1 (11.1) |
| 2 | 0 | 0 | 2 (22.2) |
| 3 | 0 | 0 | 0 |
| 4 | 0 | 0 | 0 |
| 5 | 16 (100) | 6 (100) | 6 (66.7) |
| Age (years) | 20.1 (13.7–23.2) | 20.1 (18.8–22.6) | 16.6 (9.9–22.9) |
| Weight (kg) | 66.7 (40.0–92.3) | 58.7 (48.1–120.9) | 58.97 (28.1–115.5) |
| BSA (m2) | 1.8 (1.3–2.1) | 1.6 (1.5–2.3) | 1.6 (1.0–2.4) |
| HIV RNA (copies/mL) | < 40 ( < 40–1712) | 30 ( < 20–5852) | < 40 ( < 40–372) |
| Viral load > 200 copies/mL | 2 (12.5) | 2 (33.3) | 2 (22.2) |
| CD4+ T-cell count (cells/µL) | 696 (247–1540) | 485 (108–920) | 830 (259–1463) |
Abbreviations: BSA, body surface area; HIV, human immunodeficiency virus.
*Numbers are presented as median (range) or n (%).